News 9 Oct 2026 DNDi 2026 Projects of the Year recognize teams and partners for their work to advance an open-science antiviral for future coronavirus pandemics and a single-dose treatment for sleeping sickness
Scientific articles 9 Oct 2026 A Perspective on Biomarkers, Candidates for Surrogate End Points to Accelerate Successful Development of New Antiparasitic Agents for the Treatment of Chronic Chagas Disease ACS Infectious Diseases
Press releases 6 Oct 2026 Ghana’s KNUST and DNDi partner to accelerate drug discovery for neglected diseases in Africa
Scientific articles 5 Oct 2026 Winning the endgame against sleeping sickness: Efficacy profiling of acoziborole against African trypanosomes with the focus on Trypanosoma brucei rhodesiense PLoS Neglected Tropical Diseases
Statements 25 Sep 2026 DNDi intervention at the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response at the 81st UN General Assembly
In the media 24 Sep 2026 De Etiopía a Lleida: la desigualdad mata tanto como los virus durante una pandemia El País
Scientific articles 22 Sep 2026 Efficacy and safety of alternative benznidazole and nifurtimox regimens for adults with chronic Trypanosoma cruzi infection (TESEO): an open-label, randomised, non-inferiority phase 2b trial The Lancet Infection Diseases
Scientific articles 19 Sep 2026 Thermotherapy compared with intralesional sodium stibogluconate for Leishmania aethiopica cutaneous Leishmaniasis in Ethiopia: A phase II randomized controlled trial BMC Medicine
News 15 Sep 2026 New DNDi report: Implementing Article 9.5 of the WHO Pandemic Agreement – building on current policy and practice for publicly funded R&D
In the media 9 Sep 2026 Des acteurs pharmaceutiques à but non lucratif s’allient pour faire face à la baisse des financements Swissinfo
Scientific articles 1 Sep 2026 Analysis of the therapeutic gap for Trypanosoma cruzi infection in Colombia (2012 – 2022) Memórias do Instituto Oswaldo Cruz
Scientific articles 9 Feb 2026 Repurposing oxfendazole for onchocerciasis: Population pharmacokinetics of a tablet formulation in healthy African adults CPT: Pharmacometrics & Systems Pharmacology
Scientific articles 3 Feb 2026 Evaluation of quality of care in Chagas disease cardiomyopathy Global Heart
Scientific articles 22 Jan 2026 Analysis of the consultations on the InfoChagas digital platform PLOS Neglected Tropical Diseases
Scientific articles 14 Jan 2026 Determinants of long-term SARS-CoV-2 immune responses in asymptomatic-to-moderate COVID-19 patients in sub-Saharan Africa BMC Medicine
Scientific articles 14 Jan 2026 (Un)intended consequences: a social sciences stocktake of a decade of Global Action Plan-inspired antimicrobial governance The Lancet Microbe
Scientific articles 12 Jan 2026 Dengue therapeutics consortium 2025: a global collaboration in action BMJ Global Health
Scientific articles 10 Jan 2026 Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges International Journal of Pharmaceutics X
Scientific articles 9 Jan 2026 Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis International Journal of Antimicrobial Agents
Scientific articles 9 Jan 2026 Target product profile for the development of pediatric formulations of new drugs for the treatment of children with T. cruzi infection PLOS Neglected Tropical Diseases
Scientific articles 9 Jan 2026 Global health is in crisis: to reach neglected patients, we need to reimagine medical research BMJ Global Health
Scientific articles 17 Dec 2025 Kronopolitides A–F, a family of 36-membered polyol macrolides with antiparasitic activity against Chagas disease Journal of Natural Products
Scientific articles 2 Dec 2025 The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities Parasites & Vectors
Scientific articles 25 Nov 2025 Bidirectional interaction between liposomal amphotericin B pharmacokinetics and parasite dynamics in patients with post-kala-azar dermal leishmaniasis: Potential implications for optimal dosing Clinical Pharmacology & Therapeutics
Scientific articles 20 Nov 2025 Safety, tolerability and pharmacokinetics of DNDI-6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants British Journal of Clinical Pharmacology
Scientific articles 4 Nov 2025 Host-derived molecules as novel chagas disease biomarkers: hypercoagulability markers and extracellular vesicles Methods in Molecular Biology
